Mounjaro questions, answered

Mounjaro (tirzepatide) has two approved uses on its August 2026 label: improving blood sugar, with diet and exercise, in adults and children 10 and older with type 2 diabetes, and lowering the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes at high risk. Weight loss on its own is not an approved use.

The label rules it out for three groups: people who have had medullary thyroid carcinoma or have a relative who has, people with MEN 2, and people with a past serious allergic reaction to tirzepatide. It is not recommended with severe gastroparesis. Pancreatitis history, diabetic eye disease, pregnancy plans and upcoming surgery all need discussing with your prescriber first.

Yes, for type 2 diabetes. Since December 2025 the label covers children aged 10 and older, based on SURPASS-PEDS, a trial of 99 young people with an average age of 15. Their maximum is 10 mg weekly rather than 15 mg, and the label says children should not self-inject with the KwikPen; an adult should give those injections.

Under the skin of the stomach area or the thigh, or the back of the upper arm if someone else gives it. The label says absorption is similar at all three sites. Rotate to a new spot every week, and never inject into a muscle or vein. Our how-to page walks through each device step by step.

The single-dose pen is an autoinjector used once. The single-dose vial needs a syringe and is also used once. The KwikPen and multi-dose vial each hold four weekly doses of one strength; the KwikPen must be primed before every injection, and both are discarded after four doses or 30 days. Lilly's savings card covers only the single-dose pen.

Everyone starts on 2.5 mg once a week, according to the label. The low start is there to reduce nausea, vomiting and diarrhea. After at least 4 weeks, a prescriber may raise it by 2.5 mg if blood sugar needs more control. The dosage page shows every step up to the 15 mg adult maximum.

At least 4 weeks. The label allows a 2.5 mg increase only after a minimum of 4 weeks on the current dose, and only if more glucose control is needed. Some people stay on one dose much longer. Your prescriber decides based on HbA1c, glucose readings and how well you tolerate the current step.

If no more than 4 days (96 hours) have passed, inject as soon as you remember and keep your usual day. Past that point, leave it out and resume on your normal day. Two doses must always be at least 3 days apart, per the Medication Guide.

Yes, at 36°F to 46°F in its carton, and never frozen. A single-dose pen or vial can spend up to 21 days in total unrefrigerated at up to 86°F. Four-dose KwikPens and multi-dose vials last 30 days once opened, or until the fourth dose, whichever is sooner.

Gut effects. Nausea, diarrhea, reduced appetite, vomiting, constipation, indigestion and stomach pain are the label's most common reactions, and most nausea, vomiting and diarrhea came during dose increases before easing. Nausea reached 18% at 15 mg in the placebo-controlled trials, against 4% on placebo.

It has been reported. Across the clinical trials, adjudicated acute pancreatitis occurred at 0.23 cases per 100 patient-years on Mounjaro, against 0.11 on comparators, per the label. Severe stomach pain that will not go away, sometimes reaching the back, is the warning sign; the Medication Guide says to stop Mounjaro and call your provider right away.

It is not known in humans. Tirzepatide caused thyroid C-cell tumors in rats, which is the basis of the boxed warning, but the label says human relevance has not been determined. Because of that risk, people with a personal or family history of medullary thyroid carcinoma, or with MEN 2, must not use it.

Slightly, on average. In the label's placebo-controlled pool, resting heart rate rose 2 to 4 beats per minute on Mounjaro, against 1 on placebo. Episodes of fast heart rhythm with a rise of 15 or more beats were reported in 10% on 15 mg versus 4.3% on placebo. The label calls the clinical relevance uncertain.

No. The label says Mounjaro can be injected at any time of day, with or without meals. Food timing does not change the dose. What often changes is appetite: decreased appetite was reported by 5% to 11% in the main trials, so many people find smaller meals easier.

The label does not list alcohol as an interaction. The concern is low blood sugar if you also take insulin or a sulfonylurea; the American Diabetes Association advises not drinking on an empty stomach in that case. The interactions page covers what to ask your prescriber.

It can change how fast swallowed medicines are absorbed, because it slows stomach emptying, most after the first dose. The label asks for caution with oral drugs and monitoring of narrow-margin ones like warfarin. Birth control pills are the specific case: a backup or non-oral method is advised for 4 weeks after starting and after each increase.

Yes. SURPASS-5 tested it on top of basal insulin. The label says to give them as separate injections, never mixed, and not right next to each other. Because the pair raises the risk of low blood sugar, the label tells prescribers to consider lowering the insulin dose when Mounjaro starts.

Lilly lists it at $1,112.16 per fill, which it defines as a month's supply of four pens, at every strength (Lilly pricing page, checked 5 Oct 2026). Few insured people pay that: Lilly's FAQ says almost 9 in 10 commercially insured patients pay $0 to $50 per 28 days.

Adults with commercial drug insurance that covers Mounjaro, a prescription for an approved use, and US or Puerto Rico residence. It excludes Medicare, Medicaid, TRICARE, VA and DoD members. Savings are capped at $1,950 a year, and the card ends 31 December 2026 (Lilly savings terms, checked 5 Oct 2026).

Usually not. Weight loss is not an approved Mounjaro use, so plans tend to deny it for that purpose, and Lilly's savings card also requires an approved use. Zepbound is the tirzepatide brand approved for weight management. Ask your insurer which brand is on your formulary and under what conditions.

Yes, with a prescription. LillyDirect lists Mounjaro single-dose pens for self-pay starting at $499 a month at every strength (LillyDirect, checked 5 Oct 2026). The prescription goes to LillyDirect Pharmacy, which uses partner pharmacies for home delivery or retail pickup. Terms apply.

The label does not describe what happens after stopping. Mounjaro lowers glucose while you take it, so stopping without a replacement plan is a change your prescriber should manage. Ask: "If I stop, what will control my blood sugar, and how will we monitor it?" Our guide covers what is known about stopping GLP-1 drugs.

The Mounjaro label has no conversion from semaglutide, so the starting dose is the prescriber's decision, and the two should not be taken together. The comparison page sets out how the drugs differ, including SURPASS-2, where Mounjaro was compared directly with semaglutide 1 mg.

The label sets no maximum treatment length. Its longest trial, SURPASS-CVOT, followed adults for a median of about 210 weeks, and SURPASS-4 ran up to 104 weeks. Lilly's FAQ says questions about long-term safety are best taken to your healthcare provider, who can weigh your history. Ongoing use is reviewed with your prescriber over time.

Tell your healthcare provider, as the Medication Guide directs. The label says Mounjaro should be used in pregnancy only if the benefit justifies the potential risk to the fetus, based on animal studies. Poorly controlled diabetes also carries risks in pregnancy, so the decision belongs with your prescriber.